Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Director | June 17, 2026 | June 18, 2026 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director · President and CEO | November 27, 2018 | November 30, 2018 |
| Kailera Therapeutics, Inc.KLRA · Entity 4435 | Director | April 16, 2026 | April 20, 2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC.PACB · Entity 5650 | Director | June 03, 2026 | June 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.42 · Expires 2036-06-16 | Direct | 75,000 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 75,000 · Balance 75,000 F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).
GILEAD SCIENCES, INC.
Report date November 27, 2018 · Filed November 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,574,306 |
Reported balance
After 2018-11-27 transaction · row 1
1 source rowRow 1 · 2018-11-27 · Exercise / conversion · Acquired 280,000 · Balance 1,574,306 |
| Non-qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.60 · Expires 2019-01-21 | Direct | 0 |
Reported balance
After 2018-11-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-11-27 · Exercise / conversion · Disposed 280,000 · Balance 0 F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Kailera Therapeutics, Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-04-16 | Direct | 38,300 |
Reported balance
After 2026-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 38,300 · Balance 38,300 F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.58 · Expires 2036-06-03 | Direct | 223,492 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 223,492 · Balance 223,492 F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 21:32 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001193125-26-276149 · ownership.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 21:21 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 223,492 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001299130-26-000096 · wk-form4_1780608113.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,492 Underlying: Common Stock · 223,492 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| April 16, 2026 Filed Apr 20, 2026 21:13 UTC | Kailera Therapeutics, Inc. KLRA · Entity 4435 | GrantStock Option (right to buy) · Derivative | 38,300 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-164271 · ownership.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 38,300 shares Expires 2036-04-16 F1 · derivative.exercise_date: The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:03 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0000950170-25-088484 · ownership.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2035-06-16 F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:07 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001299130-25-000133 · wk-form4_1749240442.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:58 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 32,179 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001299130-24-000152 · wk-form4_1718917116.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,179 Underlying: Common Stock · 32,179 shares Expires 2034-06-18 F2 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:58 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantCommon Stock | 22,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001299130-24-000152 · wk-form4_1718917116.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,821 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest on the one (1) year anniversary of the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| May 21, 2024 Filed May 23, 2024 23:11 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right To Buy) · Derivative | 26,791 | $0.00 Strike: $25.15 | $0.00 |
DisclosureSEC source: 0000950170-24-064210 · ownership.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,791 Underlying: Common Stock · 26,791 shares Expires 2034-05-20 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 24, 2023 Filed May 26, 2023 21:00 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 25,775 | $0.00 Strike: $11.94 | $0.00 |
DisclosureSEC source: 0001299130-23-000084 · wf-form4_168513479461225.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,775 Underlying: Common Stock · 25,775 shares Expires 2033-05-24 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| May 23, 2023 Filed May 25, 2023 23:42 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001610717-23-000073 · form4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2033-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 25, 2022 Filed May 27, 2022 23:27 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 63,015 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001299130-22-000081 · certent-form4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,015 Underlying: Common Stock · 63,015 shares Expires 2032-05-25 F1 · derivative.exercise_date: The shares subject to the option will vest monthly over one (1) year, on the same day of the month as the date of grant or, if earlier, on the date of the next annual meeting of the Company's stockholders occurring after the date of grant, provided such Reporting Person continues to serve as a director through the applicable vesting dates. Read SEC document |
| May 23, 2022 Filed May 25, 2022 23:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 33,750 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001567619-22-011721 · doc1.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2032-05-22 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| June 16, 2021 Filed Jun 22, 2021 01:18 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 12,885 | $0.00 Strike: $27.90 | $0.00 |
DisclosureSEC source: 0001299130-21-000176 · certent-form4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,885 Underlying: Common Stock · 12,885 shares Expires 2031-06-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, or, if earlier, on the date of the next annual meeting of stockholders, provided the Reporting Person continues to serve as a director through each vesting date. Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 11,250 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001567619-21-010748 · doc1.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires 2031-05-16 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| May 17, 2021 Filed May 20, 2021 00:33 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $26.89 | $0.00 |
DisclosureSEC source: 0001567619-21-010748 · doc1.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-05-16 F1 · shares: Automatically granted pursuant to the terms of the Company's non-employee director compensation program. F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan). Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 22:40 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | PurchaseCommon Stock | 100,000 | $23.00 | $2,300,000.00 |
DisclosureSEC source: 0001567619-20-021289 · doc1.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 100,000 F1 · ownership.nature: John F Milligan & Kathryn Bradford Milligan Trust. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 20:11 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001209191-20-055259 · doc4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-10-15 F1 · derivative.exercise_date: 1/3 of the shares subject to the option will vest on the one year anniversary of the date of grant, and the balance of shares will vest monthly thereafter over the next two years, provided that the Reporting Person continues to serve through each vesting date. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · derivative · entry 8 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2028-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · derivative · entry 7 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2027-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · derivative · entry 6 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $2.67 | $0.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · derivative · entry 5 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2023-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option were fully vested and exercisable. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 25,000 | $2.61 | $65,250.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 25,000 | $3.81 | $95,250.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 25,000 | $4.45 | $111,250.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 23:29 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | Exercise / conversionCommon Stock | 35,000 | $2.67 | $93,450.00 |
DisclosureSEC source: 0001209191-20-048447 · doc4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 04, 2020 Filed Aug 6, 2020 22:46 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 97,785 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001209191-20-045571 · doc4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,785 Underlying: Common Stock · 97,785 shares Expires 2030-08-04 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, or if earlier, on the date of the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director through each vesting date. Read SEC document |
| November 27, 2018 Filed Nov 30, 2018 01:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $23.60 | $0.00 |
DisclosureSEC source: 0001127602-18-034776 · form4.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 280,000 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 27, 2018 Filed Nov 30, 2018 01:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 280,000 | $23.60 | $6,608,000.00 |
DisclosureSEC source: 0001127602-18-034776 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,574,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2018 Filed May 23, 2018 20:18 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001209191-18-032585 · doc4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period. Read SEC document |
| May 04, 2018 Filed May 8, 2018 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $27.07 | $0.00 |
DisclosureSEC source: 0001127602-18-016673 · form4.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2018-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 04, 2018 Filed May 8, 2018 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 80,000 | $27.07 | $2,165,600.00 |
DisclosureSEC source: 0001127602-18-016673 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294,306 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 8,009 | $80.69 | $646,246.21 |
DisclosureSEC source: 0001127602-18-008143 · form4.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214,306 F2 · ownership.direct: The amount directly beneficially owned by the Reporting Person is restated to include 223,510 shares that was erroneously categorized as being indirectly owned in prior filings. The reported shares now includes community property shares held in a living trust of which the Reporting Person and his spouse are the sole trustees and sole beneficiaries and as to which the Reporting Person has the unilateral right to withdraw such shares. The Reporting Person does not beneficially own any shares indirectly. Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 7,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008143 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222,315 F4 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. F2 · ownership.direct: The amount directly beneficially owned by the Reporting Person is restated to include 223,510 shares that was erroneously categorized as being indirectly owned in prior filings. The reported shares now includes community property shares held in a living trust of which the Reporting Person and his spouse are the sole trustees and sole beneficiaries and as to which the Reporting Person has the unilateral right to withdraw such shares. The Reporting Person does not beneficially own any shares indirectly. Read SEC document |
| February 21, 2018 Filed Feb 24, 2018 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 48,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008143 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,214,606 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. F2 · ownership.direct: The amount directly beneficially owned by the Reporting Person is restated to include 223,510 shares that was erroneously categorized as being indirectly owned in prior filings. The reported shares now includes community property shares held in a living trust of which the Reporting Person and his spouse are the sole trustees and sole beneficiaries and as to which the Reporting Person has the unilateral right to withdraw such shares. The Reporting Person does not beneficially own any shares indirectly. Read SEC document |
| February 15, 2018 Filed Feb 24, 2018 00:07 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 340 | $62.35 | $21,198.15 |
DisclosureSEC source: 0001127602-18-008143 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,166,264 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. F2 · ownership.direct: The amount directly beneficially owned by the Reporting Person is restated to include 223,510 shares that was erroneously categorized as being indirectly owned in prior filings. The reported shares now includes community property shares held in a living trust of which the Reporting Person and his spouse are the sole trustees and sole beneficiaries and as to which the Reporting Person has the unilateral right to withdraw such shares. The Reporting Person does not beneficially own any shares indirectly. Read SEC document |
| February 01, 2018 Filed Feb 6, 2018 01:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 295,660 | $0.00 Strike: $83.49 | $0.00 |
DisclosureSEC source: 0001127602-18-004152 · form4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,660 Underlying: Common Stock · 295,660 shares Expires 2028-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 20:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001127602-17-032178 · form4.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 220,000 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 20:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 220,000 | $72.88 | $16,034,678.00 |
DisclosureSEC source: 0001127602-17-032178 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165,924 F2 · price: Sale prices reported for the transactions reported here range from $72.5201 to $73.28. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the Issuer or its shareowners upon request. Read SEC document |
| November 13, 2017 Filed Nov 15, 2017 20:19 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 220,000 | $21.58 | $4,746,500.00 |
DisclosureSEC source: 0001127602-17-032178 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,385,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported on this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 24, 2017 Filed May 25, 2017 21:28 UTC | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. PACB · Entity 5650 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.81 | $0.00 |
DisclosureSEC source: 0001209191-17-035512 · doc4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-05-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $21.58 | $0.00 |
DisclosureSEC source: 0001127602-17-008707 · form4.xml · derivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 100,000 shares Expires 2018-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013. Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 23:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 100,000 | $21.58 | $2,157,500.00 |
DisclosureSEC source: 0001127602-17-008707 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,165,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 8,389 | $70.31 | $589,830.59 |
DisclosureSEC source: 0001127602-17-007564 · form4.xml · nonDerivative · entry 4 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,065,924 Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 3,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007564 · form4.xml · nonDerivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,074,313 F3 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2014. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 02:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 11,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-007564 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,070,884 F2 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2015, and February 1, 2016. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2017 and December 31, 2018, respectively. Read SEC document |
| February 15, 2017 Filed Feb 22, 2017 02:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 315 | $59.33 | $18,688.95 |
DisclosureSEC source: 0001127602-17-007564 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,278 F1 · shares: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 02, 2017 Filed Feb 7, 2017 02:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $72.25 | $0.00 |
DisclosureSEC source: 0001127602-17-004216 · form4.xml · derivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2027-02-02 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $20.74 | $0.00 |
DisclosureSEC source: 0001127602-16-062200 · form4.xml · derivative · entry 3 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2017-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 70,000 | $77.74 | $5,442,080.00 |
DisclosureSEC source: 0001127602-16-062200 · form4.xml · nonDerivative · entry 2 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,058,963 F3 · price: Sale prices reported for the transactions reported here range from $77.265 to $77.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 06, 2016 Filed Sep 8, 2016 17:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 70,000 | $20.74 | $1,451,800.00 |
DisclosureSEC source: 0001127602-16-062200 · form4.xml · nonDerivative · entry 1 MILLIGAN JOHN F · CIK 0001191589 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.